 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | International AIDS Vaccine Initiative |
| Street 1: | 125 Broad Street |
| Street 2: | 9th Floorl |
| City: | New York |
| Province: | |
| Post Code: | 10004 |
| Country: | United States of America |
| Phone: | 212-847-1111 |
| Organization Email: | info@iavi.org |
| Web Site: | http://www.iavi.org |
| Other Online Presence: | https://www.facebook.com/AIDSvaccine/ |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | 13-3870223 |
| Organization Type - Primary: | Non-Governmental Organization |
| Organization Type - Secondary: | Other Non-Governmental Organization (NGO) |
| Organization Description: | |
| The International AIDS Vaccine Initiative (IAVI) is a global, non-profit organization whose mission is translating scientific discoveries into affordable, accessible public health solutions for HIV/AIDS, TB and other emerging infection diseases. IAVI-Aeras advances the development of new TB vaccines for the world in partnership with other biotech, pharmaceutical, and academic organizations. Together with partners and collaborators, IAVI-Aeras advances the best TB vaccine science and working toward a common goal of ending TB. Aeras is proud of the contribution it has made to the field of TB vaccine research and development and the role that it has played in two recent groundbreaking clinical efficacy trials. For more than two decades, Aeras has formed partnerships with commercial biopharmaceutical companies, other nonprofits, researchers, funders, and global health experts in its mission to advance TB vaccines for the world. | |
| Do you know about the UNHLM declaration: | Yes |
Specializations / Areas of Work | |
|
Advocacy Civil Society and Community Engagement Funding, including innovative and optimized approach to funding TB Care Research and Development Working on Key Populations related to TB |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 11 - 25 |
| Number of part-time staff who are directly involved with TB: | 1 - 5 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Involvement in TB control provision |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Network with other partners |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| We will not eliminate TB with the current vaccine and vaccination strategies available. The World Health Organization’s End TB Strategy states that a new, more effective vaccine is essential to ending TB. In fact, a widely used, more effective TB vaccine would be the single most cost-effective tool in mitigating this epidemic. Fifteen years ago, there was only one vaccine candidate in the clinical trial pipeline. Since then, IAVI-Aeras has helped develop 9 TB vaccine candidates and conducted over 35 Phase 1-2b clinical trials. Of the 12 vaccine candidates currently in human clinical trials globally, four are supported by IAVI-Aeras. Because the field will not reach success without innovation and significant investment, Aeras has also worked diligently to build coalitions among stakeholders and move TB vaccine research into the forefront of global public health discussions. |
|
Geographical Reach | |
| Which country is your headquarters located in: | United States of America |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Kenya Netherlands Rwanda South Africa Uganda United Kingdom of Great Britain and Northern Ireland United States of America Zambia |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB Care Delivery: IAVI works with partners and stakeholders to promote the importance of TB research and development, with a focus on raising awareness of the urgent funding needs for TB vaccine R&D. We have successfully advocated to governments around the world, including the U.K., Netherlands, Germany, U.S., and South Africa, to implement policies favorable to TB vaccine R&D. IAVI also partners with international advocacy organizations, including the Global TB Caucus and the Stop TB Partnership‘s Working Group on New TB Vaccines to ensure TB vaccine R&D remains a global priority. TB-HIV: There is extensive overlap among individuals and communities hit hardest by TB and HIV/AIDS; TB is the single biggest killer of people living with HIV, and, in some parts of the world, the HIV pandemic has fueled the spread of TB. The expertise of the IAVI Aeras clinical operations team and South African network will enable IAVI to strengthen its clinical development capacity and enhance its ability to address HIV, TB, and other important global health challenges. Laboratory Strengthening: eras fosters knowledge sharing and research capacity strengthening in multiple countries with a high TB burden. The value of collaborating with Aeras goes beyond the immediate benefits of successful TB vaccine research. Aeras has helped establish and support clinical research capacity throughout Africa, including trial sites in South Africa, Tanzania, and Zambia. Collateral benefits to clinical trial sites include equipment and facilities, skills development, high-quality jobs for local researchers, healthcare workers and other staff, and generally a higher standard of healthcare for trial participants. Aeras recently worked with the AIDS Vaccine Advocacy Coalition, clinical trial site staff, community advisory boards, TB Alliance and Treatment Action Group to draft Good Participatory Practice Guidelines for TB vaccine clinical trials – a set of guidelines (or standards) that any research team can apply to meaningfully involve key stakeholders in different aspects of the research, before, after, and in between trials. New TB Vaccines: The IAVI Aeras clinical development team, including a strong Cape Town based operational team, has extensive experience in conducting TB vaccine clinical trials including multi-site, multi-national trials involving thousands of participants.This team helped develop 9 TB vaccines and conducted over 35 Phase 1-2b clinical trials. Of the 13 vaccine candidates currently in human clinical trials globally, three are supported by IAVI-Aeras. IAVI-Aeras follows globally developed criteria for selecting, assessing and advancing only the most promising vaccine candidates through the research and development pipeline, which helps ensure the best stewardship of the limited funds available for TB vaccine development. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | January 22, 2019 |
| Last updated: | February 7, 2019 |